Hypercholesterolemia: Is lipid-lowering worthwhile for older patients?

Geriatrics

Volumn 55, Issue 5, 2000, Pages 22-28

  Deedwania, Prakash C ^a  

^a STANFORD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; CERIVASTATIN; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; PRAVASTATIN; SIMVASTATIN; STATIN;

CHOLESTEROL BLOOD LEVEL; CORONARY ARTERY DISEASE; DOSE RESPONSE; DRUG EFFECT; DRUG MECHANISM; HUMAN; HYPERCHOLESTEROLEMIA; LIPID BLOOD LEVEL; MEDICAL DECISION MAKING; PRIMARY PREVENTION; REVIEW; SECONDARY PREVENTION;

AGED; ANTICHOLESTEREMIC AGENTS; CORONARY DISEASE; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; MALE; MIDDLE AGED; RISK FACTORS;

EID: 0034070555     PISSN: 0016867X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (22)

1. Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. JAMA 1993; 269:3015-23.
2. Krumholz HM, Seeman TE, Merrill SS, et al. Lack of association between cholesterol and coronary heart disease mortality and morbidity and all-cause mortality in persons older than 70 years. JAMA 1994; 272:1335-40.
3. The Clinical Quality Improvement Network (CQIN) Investigators. Low incidence of assessment and modification of risk factors in acute care patients at high risk for cardiovascular events, particularly among females and the elderly. Am J Cardiol 1995; 76:570-3.
4. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998; 279:1615-22.
5. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995; 333:1301-7.
6. Malenka DJ, Baron JA. Cholesterol and coronary heart disease: The importance of patient-specific attributable risk. Arch Intern Med 1988; 148:2247-52.
7. Grundy SM. Primary prevention of coronary heart disease: Integrating risk assessment with intervention. Circulation 1999; 100:988-98.
8. Rubin SM, Sidney S, Black DM, Browner WS, Hulley SB, Cummings SR. High blood cholesterol in elderly men and the excess risk for coronary heart disease. Ann Intern Med 1990; 113:916-20.
9. Grundy SM, Cleeman JI, Rifkind BM, Kuller LH. Cholesterol lowering in the elderly population. Coordinating Committee of the National Cholesterol Education Program. Arch Intern Med 1999; 159:1670-8.
10. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344:1383-9.
11. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial Investigators. N Engl J Med 1996; 335:1001-9.
12. Lewis SJ, Moye LA, Sacks FM, et al. Effect of pravastatin on cardiovascular events in older patients with myocardial infarction and cholesterol levels in the average range: Results of the Cholesterol and Recurrent Events (CARE) trial. Ann Intern Med 1998; 129:681-9.
13. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998; 339:1349-57.
14. Vaughan CJ, Murphy MB, Buckley BM. Statins do more than just lower cholesterol. Lancet 1996; 348:1079-82.
15. Rosenson RS, Tangney CC. Antiatherothrombotic properties of statins: Implications for cardiovascular event reduction. JAMA 1998; 279:1643-50.
16. LaRosa JC. Triglycerides and coronary risk in women and the elderly. Arch Intern Med 1997; 157:961-8.
17. Hokanson JE, Austin MA. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: A meta-analysis of population-based prospective studies. J Cardiovasc Risk 1996; 3:213-9.
18. Knopp RH. Drug treatment of lipid disorders. N Engl J Med 1999; 341:498-511.
19. Aronow WS. Underutilization of lipid-lowering drugs in older persons with prior myocardial infarction and a serum lowdensity lipoprotein cholesterol >125 mg/dl. Am J Cardiol 1998; 82:668-9, A6, A8.
20. Sempos CT, Cleeman JI, Carroll MD, et al. Prevalence of high blood cholesterol among U.S. adults: An update based on guidelines from the second report of the National Cholesterol Education Program Adult Treatment Panel. JAMA 1993; 269:3009-14.
21. Goldman L, Garber AM, Grover SA, Hlatky MA. 27th Bethesda Conference: Matching the intensity of risk factor management with the hazard for coronary disease events. Task Force 6. Cost effectiveness of assessment and management of risk factors. J Am Coll Cardiol 1996; 27:1020-30.
22. Batchelor WB, Jollis JG, Friesinger GC. The challenge of health care delivery to the elderly patient with cardiovascular disease: Demographic, epidemiologic, fiscal, and health policy implications. Cardiol Clin 1999; 17:1-15.